Mazdutide, a Novel Dual Agonist, Gains First Approval for Weight Loss and Diabetes
Background
Obesity and type 2 diabetes (T2D) are pervasive metabolic disorders with significant health consequences, driving an urgent need for effective therapeutic interventions. Mazdutide (Xinermei®), developed by Eli Lilly and Company and Innovent Biologics, is a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist designed to address these conditions. This summary highlights the key milestones leading to its initial regulatory approval, marking a significant step in providing new treatment options for these widespread diseases.
Results
Mazdutide achieved its first approval in China in June 2025 for long-term body weight management. This approval targets adults with a body-mass index (BMI) of ≥ 28 kg/m2 or those with a BMI ≥ 24 kg/m2 who also present with one or more weight-related comorbidity, to be used in conjunction with diet control and increased physical activity. Subsequently, in September 2025, Mazdutide also received approval in China for glycaemic control in adults diagnosed with type 2 diabetes. Beyond these initial approvals, Mazdutide is currently undergoing further clinical evaluation for its potential use in treating metabolic dysfunction-associated fatty liver disease, obstructive sleep apnoea, and alcohol use disorder, indicating a broad therapeutic potential. These approvals represent a significant regulatory milestone for this dual agonist.
Why It Matters
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a new, potent option for managing obesity, overweight, and type 2 diabetes, conditions that affect millions globally. Its dual mechanism of action offers a distinct advantage, potentially leading to superior efficacy compared to single-receptor agonists. The ongoing clinical evaluation for conditions like metabolic dysfunction-associated fatty liver disease and obstructive sleep apnoea suggests a broader impact on metabolic health, potentially expanding its utility beyond initial indications and paving the way for future international approvals and Phase III trials.